… at 70 mg weekly and gefitinib at 250 mg daily on the basis of the phase 1 results. It enrolled
27 CRPC patients and 20 GBM patients; the phase 2 GBM patients are not included in this …

… At a median survival time of 23 months for gefitinib patients and 35 months for placebo, in
this unselected population gefitinib did not improve survival. Another field of investigation is …

… gefitinib resistance in breast cancer have shown that despite showing good initial growth
inhibitory responses to gefitinib… in mediating the acquired gefitinib resistant phenotype has also …

… Several trials have been conducted using gefitinib for treatment of NSCLC. The … patients
and compared gefitinib or placebo with either cisplatin or gemcitabine. The addition of gefitinib …

… III ISEL trial in 1692 patients with advanced NSCLC … gefitinib monotherapy (250 mg per
day), as noted previously.38 Similarly, gefitinib monotherapy did not improve survival in patients …

… predictor of the effect of gefitinib compared with carboplatin/… patients in both Asian and
non-Asian countries. Furthermore, the clinical implications and future challenges for gefitinib …

… define the course of patients following TKI discontinuation, we systematically evaluated
patients enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib. …

… response to gefitinib in NSCLC patients. More importantly, randomized Phase III studies
have shown the superiority of gefitinib compared with chemotherapy in EGFR mutant patients in …

… pathway influences the NSCLC response to gefitinib and … gefitinib treatment. In the present
studies, we show that treatment with gefitinib but not cetuximab stimulates the IGF-IR pathway …

… ability of gefitinib to inhibit the EGFR-downstream pathways was … or Ras/Erk pathways, we
investigated the effect of gefitinib in … .9, 10 To investigate the implications of EGFR, k-ras and …